<p>(<i>A</i>) Fluorescent micrographs of Oregon-green phalloidin-labeled F-actin in bEnd3 cells. (<i>B</i>) Relative F-actin intensity in bEnd3 cells and (<i>C</i>) primary human CECs. ***p≤0.001, ** p≤0.01, * p≤0.05 compare to the control; °°° p≤0.001 compare to the Aβ (1 µM) treatment group.</p
<p>(A) Monolayers were exposed to ethanol control, capsaicin (300 µM, 45 min), Jpk (2 µM, 60 min) or...
<p><b>A</b>. Non-induced control cells, as well as low, moderate and high expressers of MYOC<sub>WT<...
<p>(A) Gentamicin protection assays show that cytochalasin D (CytD), an inhibitor of actin polymeriz...
<p>(<i>A</i>) Fluorescent micrographs of fluorescently-labeled P-selectin at the bEnd3 cells. (<i>B<...
<p>Primary human PBMCs pre-incubated with DMSO, WHI-P131 or PTX were stimulated with 300 ng/mL of CX...
<p>CESCs monolayers were infected or not with the BAC20-EGFP for 6 hrs, and then treated for 4 days ...
<p>(A) RAW264.7 cells were treated with tubacin (1 µM) for 4 hours and then exposed to LPS (300 ng/m...
<p>(A) The expanded control and zVADfmk/zLLYfmk HSPCs were assessed for the polymerized actin (F act...
<p>(A) Cell shape, polarity and peripheral actin cytoskeleton pattern appear preserved upon 10 μM wi...
<p>(A) HUVECs were treated with PA, paclitaxel, cytochalasin B, or medium alone (untreated control) ...
(A) HeLa cells were pretreated with DMSO, CK666+CK869 (CKCK), Wiskostatin (WISKO), or SMIFH2, and in...
<p>A. HeLa cells were treated with different doses of jasplakinolide (Jasp). G-actin (G) and F-actin...
<p>(A) Phase-contrast (PhC) microscopy in cultured HUVECs at 72 h after siRNA transfection or 30 min...
<p>Upper panel: actin staining of: A—control cells; B, C, D—β-escin-treated cells (1, 2 and 3 μM, re...
<p><b>A, B.</b> Phenotypic characteristics of human MSCs treated with Ki16425 or vehicle alone for 4...
<p>(A) Monolayers were exposed to ethanol control, capsaicin (300 µM, 45 min), Jpk (2 µM, 60 min) or...
<p><b>A</b>. Non-induced control cells, as well as low, moderate and high expressers of MYOC<sub>WT<...
<p>(A) Gentamicin protection assays show that cytochalasin D (CytD), an inhibitor of actin polymeriz...
<p>(<i>A</i>) Fluorescent micrographs of fluorescently-labeled P-selectin at the bEnd3 cells. (<i>B<...
<p>Primary human PBMCs pre-incubated with DMSO, WHI-P131 or PTX were stimulated with 300 ng/mL of CX...
<p>CESCs monolayers were infected or not with the BAC20-EGFP for 6 hrs, and then treated for 4 days ...
<p>(A) RAW264.7 cells were treated with tubacin (1 µM) for 4 hours and then exposed to LPS (300 ng/m...
<p>(A) The expanded control and zVADfmk/zLLYfmk HSPCs were assessed for the polymerized actin (F act...
<p>(A) Cell shape, polarity and peripheral actin cytoskeleton pattern appear preserved upon 10 μM wi...
<p>(A) HUVECs were treated with PA, paclitaxel, cytochalasin B, or medium alone (untreated control) ...
(A) HeLa cells were pretreated with DMSO, CK666+CK869 (CKCK), Wiskostatin (WISKO), or SMIFH2, and in...
<p>A. HeLa cells were treated with different doses of jasplakinolide (Jasp). G-actin (G) and F-actin...
<p>(A) Phase-contrast (PhC) microscopy in cultured HUVECs at 72 h after siRNA transfection or 30 min...
<p>Upper panel: actin staining of: A—control cells; B, C, D—β-escin-treated cells (1, 2 and 3 μM, re...
<p><b>A, B.</b> Phenotypic characteristics of human MSCs treated with Ki16425 or vehicle alone for 4...
<p>(A) Monolayers were exposed to ethanol control, capsaicin (300 µM, 45 min), Jpk (2 µM, 60 min) or...
<p><b>A</b>. Non-induced control cells, as well as low, moderate and high expressers of MYOC<sub>WT<...
<p>(A) Gentamicin protection assays show that cytochalasin D (CytD), an inhibitor of actin polymeriz...